Open for inclusion

Cancer type Title Country
Breast cancer ICON CA209-9FN: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer NO
Breast cancer, Colorectal cancer, Lung cancer, Multiple diagnosis, Pancreatic cancer, Solide tumores An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors NO
Cholangiocarcinoma A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of AmphinexTM induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/ Cisplatin Chemotherapy in Patients with Advanced Inoperable Cholangioca NO
Colorectal cancer Open-label randomized trial of first-line therapy for patients with microsatellite-stable (MSS) metastatic disease using the Nordic FLOX regimen (control arm) or sequential therapy with the Nordic FLOX regimen and nivolumab (experimental arm). NO
Colorectal cancer Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial NO
Colorectal cancer Protocol for treatment under Hospital Exemption:T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting transforming growth factor beta receptor type II (TGFβII) NO
Gastric cancer A randomized phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumor (GIST) FI
Gastric cancer The stop-GIST-trial: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment. A prospective multicenter phase II trial FI
HCC, Lung cancer, Melanoma A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab) in Advanced Solid Tumors NO
Head and Neck cancer A douple blind, randomized , two-arm phase 2 study of nivolumab in combination with ipilimumab versus nivolumab in cimbination with ipilimumab placebo in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) FI
Head and Neck cancer REPORT; REirradiation and PD-1 blockade On Recurrent squamous cell head and neck Tumors NO
Hematological malignancies A phase 1/2 dose escalation safety, pharmacokinetic and efficacy study of multiple intravenous administration of a human monoclonal antibody (SAR6509848) against CD38 in patients with selected CD38+ hematological malignancies FI
Leukemia Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome FI
Leukemia A phase I multicenter open-label study of BGB324 as a single agent and in combination with cytarabine in patients with acute myeloid leukemia or high/intermediate (int-2) risk myelodysplastic syndrome wich overexpresses axl NO
Leukemia A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia NO
Lung cancer A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer NO
Lung cancer DurSab - Stereotactic Ablative Body Radiotherapy (SABR) followed by Durvalumab as maintenance treatment in patients with advanced non-small cell lung cancer not progressing after 4 to 6 cycles of first-line conventional chemotherapy SE
Lung cancer, Melanoma A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors SE
Lymphoma A phase 1/2 study of combination of pixantrone, etoposide, bendamustine and in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T- cell phenotype- The P(RE)BEN study FI
Lymphoma A Phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype – The P[R]EBEN study DK
Lymphoma A phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell Non- Hodgkin lymphoma FI
Lymphoma A Phase I/II Study of 177Lu-HH1 (Betalutin®) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma NO
Lymphoma A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL NO
Lymphoma BIO-CHIC-Study: BIOmarker driven dose intensified CHemoImmunotherapy with early CNS prophylaxis DK
Lymphoma Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk diffuse large B-cell lymphpoma FI
Lymphoma Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma (B-CAP) DK
Lymphoma Brentuxumab vedotin or B-CAP in treatment of older patients with newly diagnosed classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II- trial FI
Lymphoma Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized double-blinded Phase II trial
Melanoma A phase 1 study to evaluate safety, feasibility and immunologic response of adoptive T cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma SE
Melanoma A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. NO
Melanoma A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib Compared to Pembrolizumab or Dabrafenib Monotherapy, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma NO
Melanoma A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanom NO
Melanoma A randomized, douple-blind, phase 2/3 study of relatlimab combined with nivolumab versus nivolumab in participants with previously untreated metastatic or unresectable melanoma FI
Melanoma, Pancreatic cancer, Solide tumores A phase Ib/II open label, multicentre study of PDR001 in combination with MCS110 in patients with advanced malignancies FI
MPNST A phase II study of pembrolizumab in patients with malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery NO
Myeloma A phase 1/2 multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenaöodomide (Len) with or without dexametasone (Dex) in subjects newly diagnosed multiple myeloma (NDMM) FI
Myeloma A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma NO
Myeloma Phase II study of carfilzomib-cyclophophamide-dexamethasone and high-dose melphalan followed by randomization between observation or maintenance with carfilzomib and dexamethasone in patients with relapsed multiple myeloma after high-dose melphalan with DK
Myeloma Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT NO
Myeloma VLX1570 and low-dose dexametasone in relapsed or replaised and refractory multiple myeloma: A clinical and correlative phase 1/2 study FI
Prostate cancer Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer FI
Renal cancer A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment FI
Sarcoma A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene NO
Sarcoma Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment NO
Skin cancer A Phase 2, Open-Label, Single Arm study to evaluate the safety and efficacy of Pembrolizumab in participants with recurrent or mestastatic cutanous squamous cell carcinoma NO
Solide tumores A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) NO
Solide tumores A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) NO
Solide tumores A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors” FI
Solide tumores A phase 1/2 study of safety and efficacy of ulocuplumab combined with nivolumab in subjects with advanced or metastatic solid tumors FI
Solide tumores A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site... FI
Solide tumores An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors DK
Solide tumores An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors SE
Solide tumores An open-label, multicenter, dose-escalation phase 1b study to investigate the safety, pharmacokinetics, phamacodynamics, and therapeutic activity of RO7009789 (CD40 agonist) in combination with MPDL3280A (anti-PD-L1) in patients with locally advancedand/o DK
Solide tumores An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors NO
Solide tumores Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers DK
Solide tumores MASTIFF MTH1, A phase I, Study on Tumors Inhibition, First in human, First in class SE
Solide tumores Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy DK
Solide tumores Safety and pharmacokinetics of ODM-207 in patienst with selected advanced tumors; an open-label, non-randomosed, uncontrolled, multicentre, first-in-human study with cohort expansion FI
Solide tumores Safety and tolerability of single and repeated doses of ODM-203: an opel-label, non-randomized, uncontrolled, dose escalation, multicentre, first-in-human study in subjects with advanced solid tumors FI
Solide tumores SECAR I - Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study SE